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Abstract
Background: Cell transformation by the Src tyrosine kinase is characterized by extensive changes in gene
expression. In this study, we took advantage of several strains of the Rous sarcoma virus (RSV) to characterize the
patterns of v-Src-dependent gene expression in two different primary cell types, namely chicken embryo fibroblasts
(CEF) and chicken neuroretinal (CNR) cells. We identified a common set of v-Src regulated genes and assessed if
their expression is associated with disease-free survival using several independent human tumor data sets.
Methods: CEF and CNR cells were infected with transforming, non-transforming, and temperature sensitive
mutants of RSV to identify the patterns of gene expression in response to v-Src-transformation. Microarray analysis
was used to measure changes in gene expression and to define a common set of v-Src regulated genes (CSR
genes) in CEF and CNR cells. A clustering enrichment regime using the CSR genes and two independent breast
tumor data-sets was used to identify a 42-gene aggressive tumor gene signature. The aggressive gene signature
was tested for its prognostic value by conducting survival analyses on six additional tumor data sets.
Results: The analysis of CEF and CNR cells revealed that cell transformation by v-Src alters the expression of 6% of
the protein coding genes of the genome. A common set of 175 v-Src regulated genes (CSR genes) was regulated
in both CEF and CNR cells. Within the CSR gene set, a group of 42 v-Src inducible genes was associated with
reduced disease- and metastasis-free survival in several independent patient cohorts with breast or lung cancer.
Gene classes represented within this group include DNA replication, cell cycle, the DNA damage and stress
responses, and blood vessel morphogenesis.
Conclusion: By studying the v-Src-dependent changes in gene expression in two types of primary cells, we
identified a set of 42 inducible genes associated with poor prognosis in breast and lung cancer. The identification
of these genes provides a set of biomarkers of aggressive tumor behavior and a framework for the study of cancer
cells characterized by elevated Src kinase activity.
Background
The v-Src kinase, the product of the Rous sarcoma virus
(RSV), has provided a paradigm for the study of signal-
ing pathways and mechanisms of cell transformation by
receptor and non-receptor type tyrosine kinases. Its cel-
lular counterpart, c-Src, is a member of a small family
of kinases sharing a similar domain organization, overall
structure and regulatory mechanism. Members of the
Src family of kinases (SFK) contribute to several aspects
of the activity of receptor tyrosine kinases including
receptor turn-over, reorganization of the cytoskeleton
and the initiation of DNA synthesis [1].
A role for c-Src in the initiation or progression of
human cancer has been documented in several studies.
Elevated Src kinase activity has been observed in several
human cancers and in particular in breast, ovary, lung,
bladder, stomach and colon carcinomas [2]. The major-
ity of breast tumors samples (>70%) show elevated Src
kinase activity that reflects increased protein levels [3].
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cell transformation, c-Src likely cooperates with other
tyrosine kinases, such as the EGF receptor, frequently
over-expressed in the same tumors. An activating muta-
tion resulting in the deletion of the c-Src C-terminal
region adjacent to the negative regulatory tyrosine
(Y530) has also been identified in a subset of patients
with advanced colon carcin o m a s[ 4 ] .T h i sm u t a t i o n
mimics the oncogenic activation of v-Src, whose C-ter-
minus lacks the C-terminal Src kinase (Csk) phosphory-
lation site.
Signaling pathways controlling cell proliferation or
survival, in particular the Ras and PI3K pathways, have
been the subject of intense investigation in v-Src trans-
formed cells [5-7]. More recently, elevated Src kinase
activity has been linked to several aspects of tumorigen-
esis including modification of the tumor micro-environ-
ment, vasculogenesis, metastasis and the acquisition of
chemoresistance [8,9]. The mechanisms by which Src
controls these properties of tumor cells remain largely
unknown. One of the earliest and defining observations
of v-Src transformation is the capacity of this oncopro-
tein to modify the pattern of gene expression. This was
revealed by the cloning and characterization of genes
aberrantly expressed in v-Src transformed cells, includ-
ing genes encoding metalloproteinases and chemokines,
and the trans-acting factors regulating their expression
[10-14]. Investigations based on gene disruption or the
use of dominant-negative mutants established the
importance of transcription factors such as AP-1, mem-
bers of the STAT and Ets families, and c-Myc in the
proliferation and behavior of v-Src transformed cells
[15-22].
Gene profiling studies of transformed cells or tumors
characterized by elevated Src kinase activity have docu-
mented the changes in gene expression associated with
this oncoprotein [23-26]. However, these studies did not
assess the transformation-dependence of gene expres-
sion [23]. Often they were performed on heterogeneous
tumor specimens that limit the sensitivity of the analysis
or in immortalized cell lines that may not reveal the full
range of Src-dependent changes in gene expression. In
this study, we employ a different strategy by comparing
the expression profiles of two different primary cell
types infected by the Rous sarcoma virus, namely
chicken embryo fibroblast (CEF) and chicken neuroret-
inal cells (CNR). By using temperature sensitive or
transformation deficient mutants of v-Src, we define a
common set of genes regulated by v-Src. The expression
of a group of 42 v-Src inducible genes of the common
set was associated with reduced disease-free survival in
independent cohorts of patients with breast carcinomas.
High expression of this gene set was also observed in
primary tumors of patients with reduced bone or lung
metastasis-free survival, suggesting that the common
program of v-Src transformed cells is enriched for genes
associated with a more aggressive tumor phenotype.
The definition of this v-Src gene signature provides a
set of biomarkers for the identification of tumors with
an aggressive phenotype and the framework for the
study of cellular properties conferred by high Src kinase
activity in human tumors.
Methods
Cell culture and RSV strains
Chicken embryo fibroblasts (CEF) were isolated from
day 10 embryos while chicken neuroretinal cells (CNR)
were isolated from the retina of 7 day old embryos, as
described before [27]. CNR cells do not proliferate in
the absence of serum or a transforming v-Src kinase
and therefore were infected with the wt Schmidt Rup-
pin-A strain (SR-A) of RSV or with the temperature-
sensitive mutant ts NY72-4 RSV. CEF were infected
with the RSV strains wt SR-A, ts NY72-4 and td NY315
or with RCASBP-A, a derivative of avian sarcoma
viruses lacking a viral Src gene. All viruses belong to the
A sub-group of ASV. Characterization of the ts NY72-4
and td NY315 RSV mutants were described before
[28,29]. CNR and CEF were cultured in high glucose
Richter’s modified MEM medium (HyClone #SH30601)
supplemented with 5% cosmic calf serum (HyClone
#SH30087.03), 5% tryptose phosphate broth, glutamine,
penicillin and streptomycin. All studies were performed
with actively dividing cells cultured in medium replen-
ished the day before sample preparation to avoid starva-
tion and acidosis of the transformed cells. Populations
of ts NY72-4 RSV-infected CNR cells were expanded at
the permissive temperature of 37.5°C while CEF were
cultured at the non-permissive temperature of 41.5°C
until transferred to the permissive temperature of 37.5°C
to induce transformation. For PI3K inhibition, CEF were
treated for 8 hours with either a 100 nm dose of wort-
mannin (Biomol Research Laboratories, Pennsylvania) or
a1 5μM dose of LY290042 (Biomol Research Labora-
tories, Pennsylvania). Animal use was approved by the
McMaster University Animal Research Ethics Board
(AUP#05-06-26) and conducted in accordance with the
guidelines of the Canadian Council on Animal Care.
RNA isolation and northern blotting analysis
Total cell RNA was isolated using Trizol reagent (Invitro-
gen). Ten μg of total RNA was loaded per well and sepa-
rated on a 1.2% agarose gel containing 3.75%
formaldehyde. RNA was transferred to nylon membrane
(Schleicher & Schuell) by capillary transfer, cross-linked,
and probed with randomly primed radiolabeled DNA frag-
ments as described before [30]. Signals detected on north-
ern blots were quantified directly by phosphor-imaging
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or by scanning autoradiographs on a Umax Astra 1220 U
scanner. Images were quantified using ImageJ [31] and
adjusted for loading using GAPDH.
Gene profiling analyses
RNA samples were isolated using Trizol (Invitrogen).
RNA quality was assessed by gel electrophoresis and
examined with a Bioanalyzer (Agilent). All RNA samples
were first analyzed by northern blotting analysis and
probed for IL8 and GAPDH expression. RNA samples
with a RNA Integrity of less than 9.7 were discarded.
Microarray experiments were conducted at the Toronto
Centre for Applied Genomics (TCAG) at the Hospital
for Sick Children (Toronto, Canada). Biotinylated
cRNAs were generated at TCAG and hybridized to Affy-
metrix Chicken GeneChip arrays using standard Affy-
metrix protocols (EukGE-WS2v4). GeneChips were
scanned using the Affymetrix GeneChip Scanner 3000.
Feature intensity was quanti f i e du s i n gC o m m a n dC o n -
sole software and exported to CEL format.
CEL files were analysed using dChip software version
2007 [32]. Array data were normalized against the med-
ian intensity array for each experiment using the invar-
iant set normalization method [33]. Median array
intensities for the three experiments were scaled to the
same value prior to normalization in order to provide
comparable probe intensities for inter-experimental
comparison. Expression levels were determined by the
model-based expression index method using perfect-
match probes only [33,34]. Two-fold changes in gene
expression between experimental conditions within each
experiment were determined using log-transformed
expression values and statistical significance of expres-
sion was determined using one-way ANOVA (RCASBP/
NY315/SR-A comparison using RCASBP(A) and NY315
as control groups) or an unpaired two-tailed t-test
(NY72-4 CEF and CNR comparisons). Probe-sets whose
p-values were greater than 0.05 (pairwise comparisons)
or 0.01 (ANOVA) were excluded from further analysis.
False discovery rates in all comparisons were estimated
to be less than 3% by permutation (10,000 permutations;
[35]). For clustering, redundant genes were removed by
identifying probe-sets whose Entrez Gene and/or refer-
ence sequence IDs were identical. Probe-sets with the
lowest p-values were retained. Gene clustering was per-
formed using unsupervised hierarchal clustering by aver-
age Euclidean distance [36]. Venn diagrams were drawn
using Vennmaster v. 0.35 [37].
Experimental groups were divided into the following:
CEF infected by RCASBP(A), NY315 RSV, or SR-A RSV
(experimental group 1); CEF infected by ts NY72-4 RSV
and grown either at the permissive or non-permissive
temperature (experimental group 2); and CNR cells
infected by ts NY72-4 RSV and grown either at the per-
missive or non-permissive temperature (experimental
group 3). A minimum of three biological replicates per
experimental condition was used. An additional three
RCASBP(A)-infected CEF samples cultured at 37.5°C
were used to control for temperature effects (normalized
within experimental group 1). Temperature-regulated
genes (determined using the same criteria as for the
experimental groups) were cross-referenced to all differ-
entially expressed genes from the CEF ts NY72-4 and
CNR tsNY72-4 experiments. Genes whose change in
magnitude expression was greater than or equal to the
same genes found to be differentially expressed in the
SR-A/RCASBP(A) experiment were considered to be
temperature-regulated and not attributable to v-Src-
dependent transformation. This includes 13 genes from
the CEF ts NY72-4 and 16 genes from the CNR ts
NY72-4 experiments respectively (Additional File 1).
Arrays in each experimental group were normalized
within said experimental group to prevent skewing of
data points from tissue-effects as determined by M-A
plots for individual arrays. Array data are accessible
through the Gene Expression Omnibus http://www.ncbi.
nlm.nih.gov/geo/ using the accession number GSE14489.
Gene ontology and pathway analyses
Gene ontology (GO) analyses were conducted using the
DAVID 2.0 bioinformatics resources [38,39] functional
annotation tool using an EASE score of 0.05 and a mini-
mum of two genes per term. Pathway analyses were car-
ried out using Pathway Express software available in the
Onto-tools package [40]. Probe-sets associated with signif-
icantly differentially expressed genes from each experi-
mental group were converted to the orthologous probe
sets from the Affymetrix human U133 Plus 2.0 array.
Non-redundant orthologous probe-sets and associated
fold change differences (linear-scale) were uploaded to
Pathway Express for use in pathway analysis. Pathway ana-
lysis was conducted using default settings and only path-
ways whose corrected gamma-p-value was less than or
equal to 0.05 were kept.
Tumor data analyses
Tumor expression data sets were obtained from the
Gene Expression Omnibus at the National Center for
Biotechnological Information. Breast tumor data from
Pawitan et al.[ 4 1 ]a n dI v s h i n ae ta l . [42] were used as
training data sets (Figure 5, panels Ai and Aii respec-
tively). Breast tumor data from Minn et al. [43], colon
tumor data from the International Genomics Consor-
tium Expression Project for Oncology http://www.int-
gen.org/, and breast, lung and ovary tumor data from
Bild et al. [44] were used as test sets. All clinical data
were obtained from the original publications.
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Affymetrix arrays) for the CSR gene set were obtained
from NetAffyx (Affymetrix).
To ascertain if up-regulated genes in the CSR set
could be used as markers of poor prognosis in human
cancer, orthologous probe-sets corresponding to the up-
regulated genes in the CSR set were obtained for the
Affymetrix platforms used in the training data sets. Only
the up-regulated orthologous CSR probe-sets were used
for clustering of the Pawitan and Ivshina training sets.
Unsupervised gene and sample clustering (Pearson cor-
relation distance metric [36]) was performed on the two
training data in order to identify clusters of tumors with
similar gene expression profiles. Each tumor cluster was
subjected to survival analysis in order to identify tumor
clusters associated with poor survival. Since the objec-
tive was to identify up-regulated CSR genes associated
with poor prognosis, the genes whose expression was
statistically significantly higher in the poor-prognosis
tumor set versus the other three sets were chosen as
candidates for the aggressive gene signature (t-test, sin-
gle-tailed, p < 0.05). The common set of 42 genes iden-
tified from the two training sets defined the aggressive
gene signature.
For the test data, the sets of tumors expressing high
levels of the aggressive signature were defined as the
upper quartile of tumors from any given test set with
the highest average gene-wise mean-centered expression
of the aggressive signature set. Survival analyses were
carried out using the Kaplan-Meier product limit esti-
mator method [45] and statistical significance was evalu-
ated using the log-rank test.
Immunofluorescence and western blotting
CEFs were grown to sub-confluence on glass slides,
rinsed with PBS twice and fixed in 1% formaldehyde/
PBS for ten minutes. Cells were washed three times for
ten minutes in PBS and incubated with anti-CD44-FITC
antibody (Abcam, cat. # ab24907) for 2 hours at room
temperature and washed three times for ten minutes in
PBS. Cells were visualized on a Nikon Eclipse TE2000-U
inverted microscope. Western blotting was performed as
described before [46] using the following antibodies:
anti-GSK3-b and phospho-S9-GSK3-b (Cell Signaling
#9332 and 9336S), anti-heme oxygenase 1 (Stressgen,
#SPA-896), anti-PKB (New England Biolabs #9272),
anti-phospho-PKB (Cell Signaling #9271), anti-Erk1
(Santa Cruz Biotechnology #sc-94), and anti-Twist1
(Santa Cruz Biotechnology #sc-15393). Autoradiographs
were scanned on a Umax Astra 1220 U scanner, quanti-
fied using ImageJ and corrected for loading using Erk1
[31].
Preparation and cloning of DNA fragments
RNA was isolated from 10
7 CEFs using Trizol reagent
(Invitrogen) as per manufacturer’sd i r e c t i o n s .O n eμg
of RNA was reverse transcribed (Invitrogen Super-
Script RT) and treated with RNAse A (Invitrogen).
Double-stranded DNA probes for northern blotting
analyses were PCR amplified using Promega GoTaq
and the appropriate forward/reverse primers (Table 1).
DNA fragments were gel-purified and cloned into
pCR2.1-TA (Invitrogen) vector as per manufacturer’s
directions. All cloned products were verified by
sequencing at the MOBIX sequencing facility, McMas-
ter University. CEF4/IL8 and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) probes were generated
as described previously [30].
Results
Identification of Transformation-Regulated genes in v-Src
transformed CEF
To identify genes regulated in a transformation-depen-
dent manner, we characterized the gene expression
profiles of CEF transformed by the wt RSV strain
Schmidt Ruppin - group A (SR-A) or infected with the
Table 1 Primer sequences used for the amplification of probe DNA.
Gene Forward primer Reverse primer
CD44 TTACTCCGTACTCACATATGCC CGTCACATGCTCCTGTTCG
DKK3 AAAACCCAGCATACACACTGC CAGACTTCACACCTGCTTGG
HMOX1 CTGCCCTGGAGAAAGACTTG AAGCTCTGCCTTTGGCTGTA
ITGA1 CTCTTCTCTACATTACGACG ATTTTCTTCTTCAGTGGC
ITGA6 GTAATGGCAAATGGCTG GAACGCTGGAAGAACC
ITGA8 TGGAAAGAGGGAAGAGC AAGAAGATTGGTGGAAGG
NOV ATGAAGTGCTCCTGGGAGG GACATGGGATCTAATGGCTGG
PLCPI CTCCTCAGAACCACTGCACA TTCAAGTGTATTTTATTCTCCTGCAT
THBS2 GGGTTATTCGCCACCAAGG TAGACCTAATCGTCCACCAGC
UPP1 TATGAAGGACAGGGCAGGTT TTTCAAACGTCACAGCAAGC
VIP TAGAAAACGAGTTAGCTCCCAGGA AGAGTTTGCTAGGTGTCCTTCAGA
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RCASBP(A). NY315 RSV is a group A virus encoding
a catalytically active deletion mutant of the v-Src
kinase lacking amino acids 2-14 of the SH4 domain.
As a result of this deletion, the v-Src kinase of NY315
RSV is not myristoylated, does not associate with the
plasma membrane and is non-transforming [29].
RCASBP(A) is a group A replication competent virus
of the avian sarcoma virus family lacking an oncogene
[47]. Total cellular RNA was isolated and analyzed on
the Affymetrix chicken GeneChip, an array comprising
37,703 probe sets representing 19,881 UniGene clus-
ters. A total of 3254 probe sets, corresponding to 2904
unique genes were differentially expressed by two fold
or greater in cells infected by either NY315 or SR-A
RSV (Additional File 2). Within regulated sequences,
2455, 1691 and 730 transcripts were differentially
expressed in pair-wise comparisons between SR-A and
RCASBP(A), NY315 and RCASBP(A), and SR-A and
NY315 infected CEF, respectively.
Genes regulated in a transformation-dependent man-
ner were identified by one-way ANOVA (p≤0.01) using
RCASBP(A) and NY315 as control groups and defined by
probe sets with differences in expression greater or equal
to two-fold between any two conditions. Unsupervised
hierarchal clustering shows that transformation respon-
sive genes cluster to one of two groups, either up-regu-
lated or down-regulated in SR-A RSV transformed CEF
but not in the other two conditions (Figure 1). A total of
1095 transcripts corresponding to 418 up-regulated and
535 down-regulated genes were identified in this analysis,
defining a set of genes regulated in a transformation-
dependent fashion. Approximately 15% of these genes
were differentially expressed by five fold or more. We
refer to this set of genes as the Transformation-Regulated
genes (TR genes) of v-Src transformed CEF (Additional
File 3).
Differentially expressed genes were also characterized in
CEF infected with the temperature sensitive (ts) mutant
NY72-4 RSV. A pair-wise comparison of CEF infected
with NY72-4 revealed that 568 transcripts encoded by
477 unique genes (261 up- and 216 down-regulated)
were differentially expressed at the permissive versus
non-permissive temperatures (Figure 2 and Additional
File 4). Cross-referencing of the gene lists provided by
the SR-A/NY315/RCASBP(A) and NY72-4 RSV analyses
revealed a set of 145 non-redundant genes (or 199 tran-
scripts) corresponding to 84 down- and 61 up-regulated
genes associated with cell transformation (Additional
File 5).
To control for the effect of temperature change (cold
shock), we compared the profile of RCASBP(A) infected
CEF at the permissive temperature of 37.5°C and non-
permissive temperature of 41.5°C (Additional File 1).
Few genes were differentially expressed by a factor of
three or more at the two different temperatures. How-
ever, some of the highly v-Src responsive genes
(HMOX1, UPP1, Aquaporin 1, for instance) were also
regulated by temperature change. Genes affected by
temperature and wt v-Src, as determined by the analysis
of control and SR-A RSV-transformed CEF at 41.5°C,
indicate a sub-class of genes that are both stress-respon-
sive and v-Src-regulated.
Identification of v-Src regulated genes in chicken
neuroretinal (CNR) cells
In vertebrates, the c-Src kinase is widely expressed and
detected in most tissues. In addition, v-Src is capable of
transforming a variety of cell types in vitro [48-54]. To
compare the biological response of different cell types
RCASBP(A)
NY315
SR-A
1 2 3 1 2 3  1 2 3 4
II
I
Figure 1 Transformation regulated (TR) genes belong to two
clusters of differentially expressed genes in SR-A RSV
transformed CEF. Unsupervised hierarchal clustering was
performed on the Transformation-Regulated (TR) gene set revealing
transformation responsive genes clustering into one of two
approximately equal sized clusters. Class I includes genes up-
regulated during transformation representing approximately 44% of
the TR genes while class II comprises the down-regulated genes
(56% TR genes). The color scale indicates standard deviations from
mean centered gene expression values.
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gene expression of chicken neuroretinal (CNR) cells
infected with the temperature-sensitive mutant ts NY72-
4 RSV. Unlike CEF, neuroretinal cells do not proliferate
in vitro unless transformed by an oncoprotein such as
v-Src and cultured in serum-containing medium [55].
Therefore, ts NY72-4 RSV infected CNR are quiescent
at the non-permissive temperature of 41.5°C but are
actively dividing and transformed at the permissive tem-
perature of 37.5°C. Gene profiling analyses of CNR cells
identified 1062 transcripts, consisting of 485 up- and
577 down-regulated RNA species, with a two-fold or
greater difference in gene expression between the two
temperatures (Additional File 6). A significant fraction
of the v-Src regulated genes identified in ts NY72-4 RSV
(31%) and SR-A/NY315/RCASBP(A) infected CEF (21%)
overlapped with the corresponding set of genes in CNR
cells (Figure 2). The total number of transcripts (probe
sets) and genes differentially expressed in the three sys-
tems of v-Src transformation is provided in Table 2.
Together, the total genes regulated in these three sets
represent approximately 6% of the protein-coding genes
in the chicken genome. When all three systems are
compared, a group of 84 common genes are identified
as v-Src regulated (Figure 2; Additional File 7).
A second group of 91 genes was regulated in ts NY72-4
R S Vi n f e c t e dC E Fa n dC N Rc e l l sb u tn o ti nS R - AR S V
transformed CEF (Additional File 8). Up-regulated genes
in this list encode several important regulators of cell
proliferation or behavior including ornithine decarboxy-
lase (ODC), osteopontin, hyaluran synthase 2 (HAS2),
cyclin A and cyclin E2. In contrast, the cyclin kinase inhi-
bitor p27
Kip1 was down-regulated in NY72-4 RSV trans-
formed CEF and CNR cells. Since CNR cells are
amplified and cultured at the permissive temperature for
extensive periods of time, it is unlikely that the regulation
of these genes represents a transient effect of ts v-Src
activation. A more likely explanation for this discrepancy
is that differences in the structure of the v-Src kinase
encoded by NY72-4 and SR-A RSV account for this spe-
cificity in gene regulation. It is also likely that the list of
genes defined above (Additional File 7) is an under-
representation of the gene cohort controlled by v-Src in
CEF and CNR cells. A more accurate description of this
class of genes can be obtained by combining the genes
described in Additional File 7 and the genes regulated
uniquely in NY72-4 RSV transformed CEF and CNR cells
(Additional File 8). This combined list would then consist
of a total of 175 genes that we define as the Common set
of v-Src Regulated genes or CSR genes.
Validation and characterization of v-Src regulated genes
The expression of v-Src regulated genes was confirmed
by northern blotting analyses. In this study, the expres-
sion of genes identified by gene profiling was compared
to that of previously characterized markers of Src trans-
formation including IL8/CEF-4, CD44 and Nov
[10,14,56-58]. For all up and down-regulated genes
selected, little difference was observed between non-
transformed CEF infected with the replication compe-
tent virus RCASBP(A) and CEF infected with the trans-
formation-deficient virus NY315 RSV (Figure 3A). As
reported before, the kinetics of IL8/CEF-4 RNA accu-
mulation was biphasic and characterized by the rapid
accumulation of IL8/CEF-4 (within 1 hr) followed by a
temporary reduction of RNA level between 4 and 8 hrs
of temperature shift [59]. Other RNA species (VIP,
CD44, integrin-a-6) accumulated more slowly i.e.
between 2 and 4 hrs following ts v-Src activation and
did not show the transient down-regulation observed for
Figure 2 Euler representation of genes differentially expressed
between control and v-Src transformed cells. Comparison of
gene sets differentially expressed by two-fold between CEF or CNR
cells infected with the temperature sensitive mutant NY72-4 RSV, or
the set of Transformation-Regulated (TR) genes defined in
Additional File 3. Numbers indicate total probe sets.
Table 2 Summary of probe sets found differentially
regulated in all three systems of v-Src regulation.
Total probe-sets Unique transcripts
Analysis up down total up down Total
Transformation regulated 483 612 1095 418 535 953
CEF NY72-4 319 249 568 261 216 477
CNR NY72-4 485 577 1062 444 503 947
Number of transcripts differentially expressed in the Transformation-Regulated
dataset (RCASBP(A), NY315, SR-A RSV analysis) and the ts NY72-4 RSV infected
CEF and CNR cells is shown. Numbers under the total probe-sets heading
indicate the total number of Affymetrix probe-sets hybridizing to differentially
expressed transcripts, whereas unique transcripts do not include redundant
probe-sets whose Entrez Gene and/or reference sequence ID were identical.
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induced in cells treated with cycloheximide indicating
that the different kinetics of RNA accumulation do not
necessarily reflect a different requirement for de novo
protein synthesis (data not shown).
Cell heterogeneity was assessed by looking at the sur-
face expression of CD44 by immunofluorescence (Addi-
tional File 9). A strong CD44 signal was observed in SR-
A RSV transformed CEF but was absent in cells infected
with RCASBP(A) and NY315 RSV. All cells expressing
the ts mutant of v-Src (NY72-4 RSV) were also positive
for CD44 expression at the permissive temperature. Low
but detectable signals for CD44 expression were also
observed in ts NY72-4 RSV-infected cells at the non-
permissive temperature. This may be indicative of a cer-
tain degree of leakiness of the ts v-Src kinase, an obser-
vation accounting for the lower number of v-Src
regulated genes identified in this system.
Characterization of the common set of v-Src regulated
genes in CEF and CNR cells
Differences in the profiles of v-Src regulated genes in
CEF and CNR cells reflect in part the proliferative and
differentiation state of these cells since CNR cells do
not proliferate when non-transformed and are partially
committed to differentiation [55,60]. However, a com-
mon program of gene expression was also evident in the
profiles of v-Src transformed CEF and CNR cells. Genes
VIP
CD44
ITGA6
IL-8/CEF4
GAPDH
RCASBP(A)  
NY315 RSV 
SRA RSV 
0        1         2          4         8       24
NOV
THBS2
DKK3
ITGA1
ITGA8
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hrs  at  37.5 °C
 1      2      3                          4       5      6      7       8       9
NY72-4 
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 NY315 RSV
 SRA RSV 
 SRA RSV 
PLCPI
UPP1
HMOX1
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RCASBP(A)  
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Figure 3 Validation of gene profiling results by northern and western blotting analyses. Steady state transcript levels for a selected set of
v-Src regulated genes were determined by northern blotting analyses (A-D). CEF infected with RCASBP(A), NY315 or SR-A RSV were maintained
at 41.5°C for the duration of the analysis while NY72-4 RSV infected cells were cultured at the permissive and non-permissive temperatures of
37.5°C and 41.5°C, respectively, for the indicated period of time. AB) CEF infected with NY 72-4 RSV were grown at the non-permissive
temperature of 41.5°C and transferred to 37.5°C for the indicated period. C-D) CNR cells infected with NY 72-4 RSV were grown at the permissive
temperature of 37.5°C and either maintained at this temperature or transferred to 41.5°C for a 24 hr period before RNA isolation. CNR cells
transformed by SR-A RSV were kept at 41.5°C. RNA loading was assessed by probing for GAPDH. E) Western blotting analysis of heme oxygenase
1 (HMOX1) in CEF. Protein samples were prepared from CEF infected RCASBP(A), NY315 or SR-A RSV at 41.5°C. CEF infected with NY 72-4 RSV
were either kept at the non-permissive temperature of 41.5°C or transferred to 37.5°C for 24 hrs before lysis. Erk1 was used as a control to assess
protein loading.
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Page 7 of 17such as IL8/CEF4, VIP, HMOX1, PLCPI and UPP1,
were all activated in v-Src transformed CEF and CNR
cells. HMOX1 also provided an example of a gene with
partial activation in CEF infected with NY315 RSV, both
at the RNA and protein level (Figure 3C &3E).
A comparative analysis of v-Src regulated mRNA spe-
cies examined by northern blotting and microarray pro-
filing was performed for all mRNA species included in
Figure 3. This study revealed a strong correlation
(Spearman r of 0.83, p < 0.0001) between northern and
microarray gene expression estimates. A regression coef-
ficient of 0.91 indicates a nearly 1:1 correspondence
between northern blotting and microarray gene expres-
sion values (Additional File 10, Additional File 11). Col-
lectively the results of the immunofluorescence,
northern, and western blotting analyses validated the
expression of a sub-set of genes identified in the gene
profiling studies and illustrated the existence of a com-
mon program of gene expression controlled by v-Src in
different cell types.
Signaling pathways and biological processes regulated
during v-Src transformation
Pathways potentially regulated by v-Src-induced changes
in gene expression were identified by Pathway Express
software [40]. Pathway Express estimates whether genes
differentially expressed in a given data set impact a
given pathway by incorporating fold-change of gene
expression, where those genes are in the hierarchy of a
pathway and whether those genes are found to be statis-
tically overrepresented in that pathway. Using this meth-
odology, “ECM-receptor interaction”, “focal adhesion”
and “phosphatidylinositol signaling” were identified as
pathways most significantly altered in all three data sets
(corrected g p-value ≤ 0.05; Table 3). TGFb signaling
was also identified in CEF but not CNR cells. Several
pathways were also identified in a single data set and, in
particular, in the large cohort of the Transformation-
Regulated gene set. Thus, “leukocyte transendothelial
migration”, “complement and coagulation cascades”,
“cell adhesion molecules”, “MAPK” and “Toll-like recep-
tor signaling” pathways were all identified in this data
set (Additional File 12).
Pathway Express stresses the regulatory nature of a gene
product. This is best illustrated by the genes encoding
the pro-survival regulatory and catalytic sub-units of
PI3K, which are part of the “focal adhesion”, “PI3K” and
“leukocyte transendothelial migration” pathways and are
hallmarks of several cancer types (ex. “small cell lung
cancer”). The up-regulation of both the catalytic and
regulatory subunits of PI3K in SR-A RSV transformed
CEF implies that the pathway is strongly activated in
these cells (Additional File 3). This was confirmed by
looking at the phosphorylation status of PKB/Akt and
GSK3b, two downstream targets of the PI3K pathway.
High levels of phospho-PKB and phospho-GSK3b were
detected in SR-A RSV transformed CEF but not in cells
infected with RCASBP(A) or NY315 RSV, even when
these cells were actively cycling (Additional File 13).
The signal was reduced in cells treated with the specific
inhibitor LY294002, indicating that phosphorylation of
these proteins was dependent on the PI3K pathway.
Other important regulatory factors are included in the
list of Transformation-Regulated genes. An example is
provided by Twist1, a bHLH transcription factor pro-
moting metastasis and capable of inducing the epithe-
lial-to-mesenchymal transition (Additional Files 3 &4;
[61]). The up-regulation of Twist1, observed as a 26
kDa doublet by western blotting, was confirmed in SR-A
RSV transformed CEF (Figure 4).
Table 3 Pathway Express output summary.
#Input genes in pathway Corrected g p-value
Pathway Name # genes in
pathway
TR CEF
NY72-4
CNR
NY72-4
TR CEF
NY72-4
CNR
NY72-4
ECM-receptor interaction 87 19 10 14 1.83E-11 3.37E-06 3.14E-07
Focal adhesion 195 26 14 19 6.87E-11 1.44E-06 3.47E-06
Phosphatidylinositol signaling system 77 3 1 3 7.71E-10 4.80E-11 1.71E-03
TGF-beta signaling pathway 84 10 7 N.D. 2.90E-06 2.12E-04 N.S.
Regulation of actin cytoskeleton 208 19 N.D. 11 1.27E-05 N.S. 5.03E-03
Small cell lung cancer 86 12 6 8 2.56E-05 9.19E-03 1.26E-02
Complement and coagulation cascades 69 4 2 N.D. 1.31E-03 2.15E-02 N.S.
Epithelial cell signaling in Helicobacter pylori infection 67 3 1 N.D. 2.80E-03 1.09E-05 N.S.
Leukocyte transendothelial migration 116 7 2 7 3.19E-03 1.73E-02 2.75E-02
Type II diabetes mellitus 44 4 1 N.D. 2.60E-02 2.85E-02 N.S.
Common pathways found to be dysregulated in the Transformation-Regulated (TR), CEF NY72-4 and CNR NY72-4 gene sets are shown. The number of genes in
the pathway refers to the number of genes in the associated KEGG pathway (Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/; [102]).
Input genes refer to the number of differentially expressed genes that were found in that pathway. Corrected g p-value is a measure of significance as calculated
by Pathway Express. N.D. and N.S. indicate not determined and not significant (corrected g p-value > 0.05) respectively.
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a subset of genes associated with reduced disease-free
survival in human cancer
To test whether v-Src-induced changes in gene expres-
sion correlate with reduced disease- or metastasis-free
survival in human cancers, weu n d e r t o o kac l u s t e r i n g -
based enrichment regime to identify up-regulated genes
of the CSR set associated with this phenotype. To this
end, two independent breast carcinoma datasets with
clinical information were selected and used as training
sets. Mammary tumor sets were used because of the
abundance of good quality array data obtained on more
recent Affymetrix platforms and because a large propor-
tion of breast carcinomas (>70%) exhibit high Src activ-
ity [3]. It was also reasoned that CSR genes were more
likely to be regulated in tumors because their expression
is controlled by v-Src in different cell types (i.e. CEF
and CNR cells). The aggressive gene signature, defined
by clustering analysis, was then tested against additional,
independent tumor datasets to assess if it could be used
to predict reduced disease-free survival.
Probe-sets corresponding to orthologous genes from
the up-regulated CSR set and tumor samples from the
two independent breast carcinoma datasets [41,42] were
clustered to identify samples containing unique up-regu-
lated gene clusters associated with poor disease-free sur-
vival. Survival analyses of these tumor datasets revealed
tumor sample clusters associated with higher disease
relapse (Figure 5A). Figure 5Ai shows that sample clus-
ter 3 has poorest estimated mean disease-free survival
(5.6 years) compared to the other three clusters (7.6,
7.8, and 6.8 years; clusters 1, 2 and 4 respectively; P <
0.001). In Figure 5A, panel ii, cluster 4 has the poorest
estimated mean survival compared to clusters 1, 2 and 3
(7.8, 10.1, 10.7 and 8.4 years respectively; P < 0.01). CSR
genes that were up-regulated in the low-survival cluster
in relation to the other tumor clusters of each tumor
data set were cross-referenced to each other to generate
an aggressive tumor gene signature (Table 4, see meth-
ods). This set contains 42 unique genes overlapping
with an 80-87% concordance with respect to the genes
found differentially up-regulated in the two tumor data
training sets. This striking overlap represents over 50%
of the 80 up-regulated CSR genes (Additional Files 7
& 8 )i n d i c a t i n gt h a tt h ec o m m o np r o g r a mo fv - S r cg e n e
expression is enriched for genes associated with an
aggressive tumor phenotype. Functional classification of
these genes showed greatest enrichment for gene ontol-
ogy biological processes (GOBP) such as “Cell Cycle”
("M-phase”, “Mitosis”, “Cell Division”), “DNA Metabolic
Process” ("Response to DNA damage stimulus”),
“Response to Stress”, “Cell Proliferation” and “DNA
Replication”. (Additional File 14)
To assess whether the aggressive tumor gene signature
could be used to predict poor disease-free survival, six
independent tumor datasets were interrogated to deter-
mine if high expression of the 42 genes defining this sig-
nature was associated with a poor outcome. By
comparing the top 25% of tumors expressing the highest
l e v e l so ft h ea g g r e s s i v eg e n es i g n a t u r ea g a i n s tt h eb o t -
tom 75%, four data sets out of six showed that patients
with tumors characterized by high expression of the 42
gene cohort have reduced disease-free or metastasis-free
survival (Figure 5B). Reduced relapse-free survival was
seen in the breast and lung carcinoma datasets while
reduced lung and bone metastasis-free survival was
observed in two other breast tumor datasets.
Analysis of tumors expressing the highest levels of the
aggressive signature genes in the breast tumor set from
Minn et al., [43] indicated that the patients from whom
the tumors were derived had reduced disease-free survi-
val with respect to lung metastasis (mean estimated sur-
vival 5.4 years versus 10.1 years, P < 0.001; Figure 5Bi).
Similarly, using bone metastasis data from the same
study, the high aggressive signature expressing tumors
were associated with reduced metastasis-free survival in
patients (mean estimated survival 6.4 years versus 9.3
years, P < 0.05; Figure 5Bii). Analysis of a second breast
tumor data set [44] also shows that patients whose
tumors express high levels of the aggressive signature
genes have a reduced disease-free survival (mean esti-
mated survival 71 months versus 106 months, P < 0.02;
Figure 5Biii). Lung tumor data from the same study
indicates a similar trend where patients with tumors
expressing high levels of the aggressive signature have
reduced disease-free survival (mean estimated survival
29 months versus 54 months, P < 0.001, Figure 5Biv).
Analysis of ovarian tumor data from the same study
however did not yield any statistically significant
-Erk
-Twist1
RCASBP(A)  
NY315 RSV
SRA RSV 
  1       2       3
Figure 4 Up-regulation of Twist1 in v-Src-transformed CEF.
Twist1 protein levels are up-regulated in v-Src transformed CEF.
Two Twist1 immunoreactive protein species of 26 kDa of molecular
weight are detected in normal and v-Src transformed CEF.
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Page 9 of 17difference (data not shown). Since survival data was not
available for the colon carcinoma dataset, we asked
whether high expression of the aggressive tumor gene
signature could identify patients with distal metastases.
Analysis of the relative proportions of metastasis in
patients exhibiting high expression of the aggressive sig-
nature to those that did not, failed to show any statisti-
cally significant difference (data not shown). Taken
together, these data show that a subset of the v-Src-
regulated CSR genes correlates with poor prognosis in
patients with breast tumors, exhibiting some specificity
for metastasis to lung and bone.
Discussion
Definition of a gene signature for v-Src transformation of
primary cells
Previous gene profiling studies of v-Src transformed
cells have relied principally on the use of immortalized
rodent cell lines that may not reflect the full spectrum
of biological processes altered during v-Src transforma-
tion [24,25]. In this study, we used transformation-defi-
cient (NY315 RSV) and temperature sensitive mutants
of the Rous sarcoma virus (NY72-4 RSV) to identify
gene products regulated in a transformation-dependent
manner in primary cells. Further, all experiments were
performed in conditions promoting asynchronous cell
division and limiting acidosis. A separate study of RSV
transformed CEF was reported previously [23]. How-
ever, most of the genes identified in our studies (80%)
w e r en o ti n c l u d e di nt h eg e n es e td e s c r i b e db yt h e s e
investigators. Moreover, the results of this study differ
from ours in some important aspects. First, Masker and
co-workers did not assess the transformation-depen-
dence of differentially expressed genes since their analy-
sis was restricted to a pairwise comparison of SR-A
RSV transformed CEF and CEF infected with a replica-
tion competent virus devoid of any oncogene. Second,
several established markers of v-Src transformation such
as IL8/CEF-4 and CD44 [10,14,56], were poorly regu-
lated in their experimental conditions and did not pass
the significance criteria of the analysis. Third, Masker
and co-workers identified some transcription factors
such as c-Jun and c-Myc, as being up-regulated by v-
S r cw h i l ew ed i dn o t .W ep r e v i o u s l ye s t a b l i s h e dt h a t
early immediate genes such as c-Myc are activated by
v-Src in quiescent cells but are not differentially
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (yrs)
048
0.0
0.2
0.4
0.6
0.8
1.0
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (yrs)
Cluster 2
Cluster 3
Cluster 4
Cluster 1
P<0.001 P<0.01
024
0.0
0.2
0.4
0.6
0.8
1.0
Aggressive high
Aggressive low
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (yrs)
P<0.001
0 50 100 150
0.0
0.2
0.4
0.6
0.8
1.0
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (mo)
P<0.02
02 04 06 0
0.0
0.2
0.4
0.6
0.8
1.0
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (mo)
P<0.001
AB
Lung metastasis-free  survival 
          (breast tumor data)
Disease-free survival 
 (breast tumor data)
Disease-free survival 
    (lung tumor data)
036
0.0
0.2
0.4
0.6
0.8
1.0
l
a
v
i
v
r
u
S
 
f
o
 
y
t
i
l
i
b
a
b
o
r
P
Survival Time (yrs)
P<0.05
Bone metastasis-free  survival
          (breast tumor data)
Aggressive high
Aggressive low
Aggressive high
Aggressive low
i i i
v i i i i
i i i
Cluster 2
Cluster 3
Cluster 4
Cluster 1
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
036
0.0
0.2
0.4
0.6
0.8
1.0
Aggressive high
Aggressive low
Figure 5 A subset of CSR genes predicts poor prognosis in human tumors. A) Hierarchal clustering of two breast tumor datasets with
respect to up-regulated CSR genes reveals tumor sample clusters associated with low disease-free survival (cluster 3 in panel i and cluster 4 in
panel ii). The color scale beneath the heat maps indicates standard deviations from mean centered gene expression values. Colors of survival
curves correspond to the colored clusters indicated in the heat maps above each survival plot. B) A common set of up-regulated genes
associated with low-survival clusters in panel A, termed the aggressive tumor gene signature (Table 4), correlates with poor prognosis in several
patient cohorts. Tumor clusters expressing high levels of the aggressive signature genes (aggressive high) correlate with lower lung and bone
metastasis-free survival in patients with breast tumors (i and ii), as well as with lower disease-free survival in separate cohorts of patients with
breast (iii) or lung tumors (iv).
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Page 10 of 17expressed when actively dividing cells are compared
[14]. Therefore, some of these differences may reflect
the experimental conditions of the studies and, in parti-
cular, the conditions of cell culture.
A study performed with ts NY72-4 v-Src identified a
limited number of v-Src regulated genes in NIH 3T3
fibroblasts [26]. Key transcriptional regulators identified
by these authors, such as Hmga2 (high mobility group
AT-hook2) and Id4 (inhibitor of DNA binding 4), are
also included in the list of v-Src-regulated genes in CNR
cells (Additional File 6). In addition, Liu and co-workers
described the regulation of important regulators of the
cell cycle and angiogenesis by SSeCKS, a metastasis-sup-
pressor gene down-regulated by v-Src [26]. Interestingly,
tumor suppressor genes such as DKK3 and gamma
FBPa, the avian homolog of HIC-1 (hypermethylated in
cancer 1), were repressed markedly by v-Src in CEF.
Thus, the abrupt down-regulation of tumor-suppressor
genes may be required for v-Src-dependent cell transfor-
mation (Figure 3 and Additional File 3; [26]).
The common set of v-Src regulated genes (CSR genes) is
enriched for genes associated with an aggressive tumor
phenotype
Since the c-Src kinase is expressed ubiquitously in most
vertebrate tissues, we reasoned that genes regulated by
v-Src in multiple cell types would better represent tar-
gets of this kinase in tumorigenesis. Using CEF and
CNR cells, we thus described a common program of
gene expression consisting of 175 genes regulated by v-
Src in both cell types. This program, referred to as the
Common set of v-Src Regulated genes or CSR genes,
was then used to interrogate several independent tumor
data sets with corresponding clinical information. Begin-
ning with data from two independent cohorts of breast
carcinomas as training sets, we performed hierarchal
clustering analyses to identify a group of v-Src inducible
genes highly expressed in tumors associated with
reduced disease-free survival (Table 4). Significantly, the
majority (80-87%) of the 42 genes included in this
group were identified in both independent tumor data
sets. Since the CSR gene cohort consists of a total of 80
up-regulated genes, the 42 genes identified in this analy-
sis suggest that CSR genes are highly enriched for genes
associated with a more aggressive tumor phenotype. To
confirm this finding, we then interrogated several addi-
tional tumor data sets including some used previously
by other investigators [43,44]. This analysis confirmed
the expression of the v-Src inducible gene set in pri-
mary tumors of patients with reduced disease-free or
metastasis-free survival in four of six tumor data sets,
including breast and lung carcinomas (Figure 5). In
Table 4 v-Src aggressive tumor gene signature.
Gene
symbol
Gene name
ATAD3A ATPase family, AAA domain containing 3A
C13orf3 chromosome 13 open reading frame 3
CCNA2 cyclin A2
CCNE2 cyclin E2
CEP55 centrosomal protein 55 kDa
CSTA cystatin A (stefin A)
E2F8 E2F transcription factor 8
EAF2 ELL associated factor 2
EXO1 exonuclease 1
GAR1 GAR1 ribonucleoprotein homolog (yeast)
HELLS helicase, lymphoid-specific
HMOX1 heme oxygenase (decycling) 1
HSP90AB1 heat shock protein 90 kDa alpha (cytosolic), class B
member 1
IL8 Interleukin 8
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-
4 receptor)
KIF11 kinesin family member 11
KIF2A kinesin heavy chain member 2A
LBR lamin B receptor
MPP1 Membrane protein, palmitoylated 1, 55 kDa
NASP nuclear autoantigenic sperm protein (histone-binding)
NOC2L nucleolar complex associated 2 homolog (S. cerevisiae)
NOP14 NOP14 nucleolar protein homolog (yeast)
NPM3 nucleophosmin/nucleoplasmin, 3
ODC1 ornithine decarboxylase 1
PDCD6 programmed cell death 6
PLAU plasminogen activator, urokinase
RIOK3 RIO kinase 3 (yeast)
RRM1 ribonucleotide reductase M1
RRM2 ribonucleotide reductase M2 polypeptide
SHC4 SHC (Src homology 2 domain containing) family, member
4
SLC2A14 solute carrier family 2 (facilitated glucose transporter),
member 14
SLC2A3 solute carrier family 2 (facilitated glucose transporter),
member 3
SLC36A4 solute carrier family 36 (proton/amino acid symporter),
member 4
SOCS1 Suppressor of cytokine signaling 1
TRIP13 thyroid hormone receptor interactor 13
TTC35 tetratricopeptide repeat domain 35
UHRF1 ubiquitin-like with PHD and ring finger domains 1
UPP1 uridine phosphorylase 1
USP1 ubiquitin specific peptidase 1
USP18 ubiquitin specific peptidase 18
VRK1 vaccinia related kinase 1
ZDHHC21 zinc finger, DHHC-type containing 21
Aggressive gene signature used as a predictor of poor prognosis as
determined by hierarchal clustering enrichment regime (see text, Figure 5).
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Page 11 of 17contrast, no correlation was observed for ovarian and
colon carcinomas suggesting tissue specificity of the v-
Src aggressive tumor gene signature. A recent report by
Zhang and co-investigators shed some light on the role
of Src in bone metastasis of breast cancer cells [9].
K n o c k d o w no fc - S r ci nt h eh i g h l ym e t a s t a t i ch u m a n
BoM-1833 cell line impaired the proliferation of these
cells in the bone micro-environment but had no effect
on lymph node metastasis in a mouse model. Moreover,
these authors provided evidence that Src enhanced the
survival of the metastatic cancer cell line by mediating
the activation of PKB/Akt in response to CXCR4 activa-
tion [9].
Prognostic gene signatures for breast cancer have
been described previously by several groups [62-66]. A
comparative analysis of the 70-gene, 76-gene and the
Gene expression Grade Index (GGI) signatures
revealed that they have similar prognostic ability
despite limited overlap in gene identity [64]. Recently,
Yu et al. showed that a common set of biological pro-
cesses is enriched among these gene signatures even
when defined by different genes. For instance, “Cell
Cycle” is enriched in the 70-gene, 76-gene and the 97-
gene GGI signatures even though cyclin E2 (CCNE2)
is the only gene of this pathway common to all three
signatures [63,65-67]. Interestingly, CCNE2, the only
gene found in more than two signatures [67] was also
identified in our aggressive gene signature along with
EXO1 and KIF11, found in two other studies [62,63]
(Table 4). Functional classification of our 42-gene
aggressive signature shows that three of the 16
enriched GOBP terms ("Cell Cycle”, “Mitosis” and
“DNA replication”) are identical to three of the 36
core GOBP terms described by Yu et al.T w e l v e
remaining terms from our aggressive signature map to
parent terms of one or more of the 36 core terms
while two, “blood vessel morphogenesis” and “cell pro-
liferation”, are unique to our gene set (Additional File
14). This similarity in enriched processes shared with
other breast cancer signatures reinforces the hypoth-
esis that there is a common aggressive tumor “path-
way-signature” [67].
Biological processes defined by the CSR gene signature -
DNA damage and the stress response
Several genes of the DNA damage and stress responses
are included in the 42 genes of the aggressive tumor sig-
nature. DNA damage resulting from the production of
reactive oxygen species (ROS) or DNA replication stress
has been observed in cells transformed by several onco-
genes [68-72]. However, evidence of DNA damage, as
indicated by the levels of g H2AX, is presently lacking
in v-Src transformed CEF (our unpublished results).
Therefore, the pathways responsible for the production
of ROS or replicative stress may be attenuated in these
cells. Src-transformed cells are known to be more resis-
tant to conditions of oxidative stress and the induction
of genes such as HMOX1 or UPP1 enhance cell survival
in conditions of hypoxia or glucose depletion i.e. in con-
ditions promoting the production of ROS [73-77].
Therefore, genes of the aggressive tumor signature may
limit the effects of oncogenic stress and provide a survi-
val advantage to the cell.
Several genes identified in this study were also regu-
lated in response to temperature change (cold shock).
Since temperature change had a modest effect on the
activation of these genes with induction levels of 3-fold
or less (Additional File 1), and since all v-Src regulated
genes affected by temperature change were also identi-
fied in the RCASBP/NY315/SR-A RSV analysis at 41.5°
C, it is unlikely that these genes represent a class of
genes regulated uniquely as a result of temperature
change. Genes like HMOX1, Aquaporin 1 and the
metallothioneins MT2A and 3 are induced in response
to a wide variety of stress conditions and are widely
regarded as general stress response genes. Since
HMOX1, Aquaporin 1 and UPP1 are activated by tem-
perature change and are included in the Common Set of
v-Src Regulated (Additional Files 7 &8), they may be
part of a general and previously unrecognized stress-
response program controlled by v-Src.
Biological processes affected by v-Src transformation:
Motility and Invasiveness
The large cohort of Transformation-Regulated genes
(TR genes; Additional File 3) includes several genes
that may contribute to a more aggressive tumor phe-
n o t y p e .S r c - t r a n s f o r m e dC E F sa r eh i g h l ym o t i l ea n d
characterized by structures mediating cell migration
called podosomes [78,79]. Like the related invadopodia
described in other cancer cells, the podosomes are
actin-rich structures closely associated with adhesion
molecules and ECM-degrading enzymes such as the
matrix metalloproteinases MMP-1, MMP-2 or MMP-9
[80]. In CEF, v-Src transformation stimulated the
expression of four critical regulators of actin polymeri-
zation and podosome formation, namely N-WASP,
cortactin, gelsolin and the p41 subunit of the actin
related protein complex 2/3 (Arp 2/3 subunit 1b-p41;
Additional File 3[81-84]). Two of these factors (Arp 2/
3 subunit 1b-p41 and cortactin) were also activated in
CNR cells indicating that v-Src controls the expression
of these genes in diverse cell types (Additional File 6).
The gene encoding the p41 subunit of the Arp2/3
complex is frequently amplified in pancreatic cancer
and is a regulator of the motility and invasion of pan-
creatic cell lines [85]. In contrast, caldesmon and
transgelin were repressed by v-Src in CEF. Transgelin
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podosome formation. In particular, transgelin is a
negative regulator of MMP-9 expression and a sus-
pected tumor suppressor [86,87]. Independent studies
have shown that caldesmon, an actin filament cross-
linker, antagonizes the action of the Arp 2/3 complex
and is a negative regulator of podosome formation and
invasion in transformed cells [88-90]. Therefore, v-Src
transformation is characterized by changes in gene
expression promoting the dynamic remodeling of the
actin cytoskeleton and the assembly of podosomes. It
is also significant that wt v-Src induces the expression
of the p110δ catalytic subunit, a PI3K isoform required
for cell migration in macrophages and breast cancer
cells (TR genes; Additional File 3; [91,92]).
Biological processes affected by v-Src transformation:
Epithelial-to-mesenchymal transition and drug resistance
Several studies have linked the expression of v-Src and
other Src family kinases to resistance of a variety of che-
motherapeutic agents including cisplatin, geftinib, pacli-
taxel, oxaliplatin and tamoxifen [93-97]. Since
chemoresistance is often associated with increased cell
motility and invasiveness, it has been suggested that v-Src
controls these activities by inducing the epithelial-to-
mesenchymal transition (EMT) in tumor cells [8]. In sup-
port of this notion, Sham and co-workers reported
recently that the up-regulation of the basic-helix-loop-
helix factor Twist1 by NF-kB increases chemoresistance of
PC3 prostate cancer cells treated with daunorubicin or cis-
platin [98]. In a separate report, Cheng et al.i d e n t i f i e d
Twist1 and its target Akt2/PKBb as factors contributing to
the metastatic potential of highly invasive breast carci-
noma cell lines. In the same study, these investigators
showed that Twist1 and Akt2/PKBb determine the resis-
tance of these cells to paclitaxel [99]. Twist1 is a potent
i n d u c e ro ft h eE M Ta n dam e m b e ro ft h eT r a n s f o r m a -
tion-Regulated gene cohort identified in this study (Figure
4 and Additional File 3). Since forced expression of Twist1
is sufficient to induce the EMT in mammary epithelial
cells, the regulation of this factor provides a mechanism
by which v-Src may induce the EMT and enhance che-
moresistance [61]. Twist1 is not the only marker of the
EMT identified in this study since N-cadherin mRNA
expression was also up-regulated in SR-A transformed
CEF (TR genes; Additional File 3).
Conclusion
Elevated Src kinase activity has been described in sev-
eral unrelated human tumors and in cells derived from
these tumors [2]. In human cancers, high Src activity
correlates with progression to a more malignant phe-
notype and the increased metastatic potential of tumor
cells [4,100,101]. In this study, we define a signature of
42 v-Src inducible genes whose expression is asso-
ciated with reduced disease-free survival in breast and
lung cancer patients from several independent studies.
In one dataset, this 42 gene signature was also asso-
ciated with reduced bone and lung metastasis-free sur-
vival. Several genes of the larger cohort of
Transformation-Regulated Genes (TR genes) have also
been associated with features of aggressive tumors
such as invasiveness and chemoresistance. These genes
provide a set of biomarkers and candidate therapeutic
targets for the treatment of patients with tumors char-
acterized by more aggressive behavior. The functional
characterization of these genes represents a roadmap
for the study of tumor cells characterized by elevated
Src kinase activity.
Additional file 1: Temperature regulated genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S1.CSV]
Additional file 2: Pairwise comparisons of CEF infected with RCASBP
(A), NY315, or SRA RSV.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S2.CSV]
Additional file 3: Transformation-Regulated genes in CEF.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S3.CSV]
Additional file 4: Genes regulated by ts NY72-4 infected CEF.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S4.CSV]
Additional file 5: v-Src regulated genes identified in SR-A and ts
NY72-4 RSV transformed CEF.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S5.CSV]
Additional file 6: Genes regulated by ts NY72-4 infected CNR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S6.CSV]
Additional file 7: Genes commonly regulated in all three v-Src
transformed cell systems.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S7.DOC]
Additional file 8: Genes uniquely regulated in NY72-4 RSV
transformed CEF and CNR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S8.DOC]
Additional file 9: Expression of CD44 in normal and transformed
CEF. Surface expression of CD44 was examined by immunofluorescence
in CEF infected with RCASBP(A), NY315 or SR-A RSV. NY72-4 infected CEF
were either grown at the non-permissive (41.5°C) or the permissive
temperature (37.5°C) for 24 hours prior to fixing and staining for CD44.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S9.PDF]
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Page 13 of 17Additional file 10: Comparison of expression data of v-Src
regulated genes as determined by gene profiling and northern
blotting analyses. Gene expression by northern blotting analysis (Figure
3) was quantified and analyzed against microarray data to confirm a
correlation in gene expression as measured by the two methods.
Analysis of correlation of log2-transformed gene expression ratios (log2
(experimental/baseline)) indicates a strong correlation (Spearman r of
0.83; p < 0.0001) between northern blot and microarray gene expression
estimates. This r value is higher than typically observed in array
validations [103], and consistent with northern blotting as a superior
method of gene expression validation [104]. A slope of 0.91 for the
regression line indicates a nearly 1:1 ratio between log2 expression ratios
of northern and microarray data.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S10.PDF]
Additional file 11: Comparison of gene expression data quantified
from northern blots (Figure3) compared to values obtained from
microarray analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S11.DOC]
Additional file 12: Full Pathway Express output summary. Common
pathways found to be dysregulated in the Transformation-Regulated (TR),
CEF NY72-4 and CNR NY72-4 gene sets are shown. The number of genes
in the pathway refers to the number of genes in the associated KEGG
pathway. Input genes refer to the number of differentially expressed
genes that were found in that pathway. Corrected g p-value is a measure
of significance as calculated by Pathway Express. N.D. and N.S. indicate
not determined and not significant (corrected g p-value > 0.05)
respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S12.DOC]
Additional file 13: Activation of the PI3K/PKB-Akt pathway in v-Src-
transformed CEF. The activation of PKB-Akt in RCASBP(A), NY315 and
SR-A RSV infected CEF was investigated by western blotting analysis.
Antibodies for PKB-Akt and the Ser-473 phosphorylated form of PKB-Akt
were used to determine the expression and activation of PKB-Akt,
respectively. The level of phospho-PKB-Akt was examined in cells treated
with 1% DMSO (D; diluent) or the PI3K inhibitors LY290042 (LY) and
wortmannin (W). PKB-Akt was hyper-phosphorylated in v-Src transformed
CEF but phospho-PKB-Akt levels decreased upon treatment with the PI3K
inhibitors. The activation of PKB-Akt coincided with increased Ser-9
phosphorylation of GSK3-b.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S13.PDF]
Additional file 14: GO biological process terms most enriched in the
aggressive gene signature.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
41-S14.DOC]
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